• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.一项关于罗米地辛与异环磷酰胺、卡铂、依托泊苷联合治疗复发或难治性外周T细胞淋巴瘤患者的I期研究。
Haematologica. 2018 Sep;103(9):e416-e418. doi: 10.3324/haematol.2018.187617. Epub 2018 Apr 5.
2
Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T-cell lymphoma.在复发/难治性外周 T 细胞淋巴瘤中，使用 Brentuximab-vedotin 联合异环磷酰胺、卡铂、依托泊苷。
Eur J Haematol. 2021 Apr;106(4):467-472. doi: 10.1111/ejh.13568. Epub 2020 Dec 22.
3
DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.地舒单抗与 ICE 挽救方案在自体移植治疗复发/难治性侵袭性外周 T 细胞淋巴瘤中的应用：一项单中心平行患者队列的回顾性评估。
Ann Hematol. 2013 Aug;92(8):1041-8. doi: 10.1007/s00277-013-1738-9. Epub 2013 Mar 27.
4
Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.异环磷酰胺-卡铂-依托泊苷（ICE）与阿糖胞苷-顺铂-地塞米松（DHAP）作为复发或难治性淋巴瘤患者挽救性化疗的比较
Cancer Invest. 2008 May;26(4):401-6. doi: 10.1080/07357900701788098.
5
Feasibility and usefulness of high-dose chemotherapy (high-dose ifosfamide, carboplatin and etoposide) combined with peripheral blood stem cell transplantation for male germ cell tumor: a single-institute experience.高剂量化疗（高剂量异环磷酰胺、卡铂和依托泊苷）联合外周血干细胞移植治疗男性生殖细胞肿瘤的可行性和实用性：单机构经验
Anticancer Drugs. 2006 Oct;17(9):1057-66. doi: 10.1097/01.cad.0000231469.46664.12.
6
Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma.在复发/难治性外周 T 细胞淋巴瘤中，如果根据 CD30 阳性使用异环磷酰胺、卡铂和依托泊苷联合 Brentuximab vedotin 或 Romidepsin。
Cancer Rep (Hoboken). 2022 Jul;5(7):e1581. doi: 10.1002/cnr2.1581. Epub 2022 Mar 8.
7
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.复发侵袭性淋巴瘤的治疗：含与不含高剂量治疗及干细胞救援的方案
Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12.
8
Salvage chemotherapy for relapsed and resistant lymphoma with a carboplatin containing schedule--EPIC.含卡铂方案的挽救性化疗用于复发和难治性淋巴瘤——EPIC研究
Hematol Oncol. 1994 May-Jun;12(3):125-8. doi: 10.1002/hon.2900120304.
9
High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.卡铂、依托泊苷和异环磷酰胺大剂量治疗后行自体干细胞移植治疗复发或难治性生殖细胞癌：一项I/II期研究。德国睾丸癌协作研究组。
J Clin Oncol. 1994 Jun;12(6):1223-31. doi: 10.1200/JCO.1994.12.6.1223.
10
Durable Response in Relapsed Adolescent Peripheral T-cell Lymphoma: A Case Report and Review of the Literature.复发青少年外周 T 细胞淋巴瘤的持久缓解：病例报告及文献复习。
J Pediatr Hematol Oncol. 2022 Jan 1;44(1):e278-e281. doi: 10.1097/MPH.0000000000002147.

引用本文的文献

1
Management of T-cell malignancies: Bench-to-bedside targeting of epigenetic biology.T细胞恶性肿瘤的管理：从 bench 到床边的表观遗传生物学靶向治疗
CA Cancer J Clin. 2025 Jul-Aug;75(4):282-307. doi: 10.3322/caac.70001. Epub 2025 Apr 15.
2
Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma.复发/难治性外周 T 细胞淋巴瘤的新型临床风险分层和治疗策略。
J Hematol Oncol. 2024 Jun 1;17(1):38. doi: 10.1186/s13045-024-01560-7.
3
Peripheral T-Cell Lymphomas: Therapeutic Approaches.外周T细胞淋巴瘤：治疗方法
Cancers (Basel). 2022 May 8;14(9):2332. doi: 10.3390/cancers14092332.
4
Treatment outcomes of T and natural-killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy.异环磷酰胺、卡铂和依托泊苷化疗治疗T细胞和自然杀伤/T细胞淋巴瘤的疗效
Cancer Rep (Hoboken). 2022 Sep;5(9):e1552. doi: 10.1002/cnr2.1552. Epub 2022 Apr 28.
5
Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma.在复发/难治性外周 T 细胞淋巴瘤中，如果根据 CD30 阳性使用异环磷酰胺、卡铂和依托泊苷联合 Brentuximab vedotin 或 Romidepsin。
Cancer Rep (Hoboken). 2022 Jul;5(7):e1581. doi: 10.1002/cnr2.1581. Epub 2022 Mar 8.
6
Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas.复发/难治性外周 T 细胞淋巴瘤的分子靶向治疗。
Semin Hematol. 2021 Apr;58(2):78-84. doi: 10.1053/j.seminhematol.2021.02.004. Epub 2021 Mar 3.
7
Novel targeted therapies of T cell lymphomas.T 细胞淋巴瘤的新型靶向治疗。
J Hematol Oncol. 2020 Dec 31;13(1):176. doi: 10.1186/s13045-020-01006-w.
8
Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy.癌症治疗中靶向组蛋白乙酰转移酶、组蛋白去乙酰化酶和溴结构域蛋白的小分子
Front Oncol. 2020 Nov 11;10:560487. doi: 10.3389/fonc.2020.560487. eCollection 2020.
9
Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report.西达本胺治疗肝脾T细胞淋巴瘤的疗效：一例报告。
World J Clin Cases. 2020 Jul 26;8(14):3122-3129. doi: 10.12998/wjcc.v8.i14.3122.
10
Symphony of epigenetic and metabolic regulation-interaction between the histone methyltransferase EZH2 and metabolism of tumor.组蛋白甲基转移酶 EZH2 与肿瘤代谢的表观遗传和代谢调控的相互作用
Clin Epigenetics. 2020 May 24;12(1):72. doi: 10.1186/s13148-020-00862-0.

本文引用的文献

1
Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.罗米地辛可使复发或难治性血管免疫母细胞性T细胞淋巴瘤患者产生持久反应。
Hematol Oncol. 2017 Dec;35(4):914-917. doi: 10.1002/hon.2320. Epub 2016 Jul 12.
2
Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.罗米地辛联合环磷酰胺、多柔比星、长春新碱和泼尼松用于既往未接受治疗的外周T细胞淋巴瘤患者：一项非随机1b/2期研究
Lancet Haematol. 2015 Apr;2(4):e160-5. doi: 10.1016/S2352-3026(15)00023-X. Epub 2015 Mar 17.
3
Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. upfront 异基因造血干细胞移植治疗未经治疗的局限性外周 T 细胞淋巴瘤患者：单中心意向治疗分析。
Ann Oncol. 2015 Feb;26(2):386-92. doi: 10.1093/annonc/mdu515. Epub 2014 Nov 12.
4
Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma.新诊断的外周 T 细胞淋巴瘤患者强化化疗免疫治疗联合或不联合干细胞移植。
Leukemia. 2014 Sep;28(9):1885-91. doi: 10.1038/leu.2014.79. Epub 2014 Feb 20.
5
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.罗米地辛治疗复发/难治性外周T细胞淋巴瘤：关键研究更新显示疗效持久。
J Hematol Oncol. 2014 Jan 23;7:11. doi: 10.1186/1756-8722-7-11.
6
Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.系统性成熟 T 细胞非霍奇金淋巴瘤的造血细胞移植。
J Clin Oncol. 2013 Sep 1;31(25):3100-9. doi: 10.1200/JCO.2012.46.0188. Epub 2013 Jul 29.
7
Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.外周 T 细胞淋巴瘤患者首次复发或进展后的生存情况：疾病谱和罕见的长期幸存者。
J Clin Oncol. 2013 Jun 1;31(16):1970-6. doi: 10.1200/JCO.2012.44.7524. Epub 2013 Apr 22.
8
DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.地舒单抗与 ICE 挽救方案在自体移植治疗复发/难治性侵袭性外周 T 细胞淋巴瘤中的应用：一项单中心平行患者队列的回顾性评估。
Ann Hematol. 2013 Aug;92(8):1041-8. doi: 10.1007/s00277-013-1738-9. Epub 2013 Mar 27.
9
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.罗米地辛治疗外周 T 细胞淋巴瘤患者的 2 期临床试验。
Blood. 2011 Jun 2;117(22):5827-34. doi: 10.1182/blood-2010-10-312603. Epub 2011 Feb 25.
10
Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.在接受减低剂量预处理后进行异基因造血细胞移植的复发外周T细胞非霍奇金淋巴瘤中移植物抗淋巴瘤效应
J Clin Oncol. 2004 Jun 1;22(11):2172-6. doi: 10.1200/JCO.2004.12.050.

A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

作者信息

Strati Paolo, Chihara Dai, Oki Yasuhiro, Fayad Luis E, Fowler Nathan, Nastoupil Loretta, Romaguera Jorge E, Samaniego Felipe, Garg Naveen, Feng Lei, Wesson Emily T, Ruben Charnelle E, Stafford Mildred D, Nieto Yago, Khouri Issa F, Hosing Chitra, Horowitz Sandra B, Kamble Rammurti T-, Fanale Michelle A

机构信息

Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA.

Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA.

出版信息

Haematologica. 2018 Sep;103(9):e416-e418. doi: 10.3324/haematol.2018.187617. Epub 2018 Apr 5.

DOI:10.3324/haematol.2018.187617
PMID:29622656
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6119133/
Abstract
摘要